Press Releases

2016

June 09, 2016 Aduro Biotech to Present at NASDAQ Investor Conference

June 04, 2016 Aduro Biotech Presents Encouraging Anti-Tumor Response Data From Ongoing Phase 1b Study in Malignant Pleural Mesothelioma at ASCO

May 16, 2016 Aduro Biotech Announces Phase 2b ECLIPSE Trial Misses Primary Endpoint in Heavily Pretreated Metastatic Pancreatic Cancer

May 15, 2016 Aduro Biotech to Host Conference Call

May 12, 2016 Aduro Biotech Announces First Patient Dosed in Phase 1 Study of ADU-S100 for the Treatment of Cutaneously Accessible Tumors

May 11, 2016 Aduro Biotech Announces Management Promotions

May 02, 2016 Aduro Biotech Announces First Quarter 2016 Financial Results

April 28, 2016 Aduro Biotech Announces Key Preclinical Data Published Highlighting New Approach to Treat Multiple Myeloma

April 27, 2016 Aduro Biotech to Present at Two Upcoming Investor Conferences

April 11, 2016 Aduro Biotech Chief Scientific Officer to Highlight the Potential of STING Activation in Cancer Immunotherapy in a Major Symposium at the 2016 American Association for Cancer Research Annual Meeting

March 28, 2016 Aduro Biotech and UC Berkeley Launch Industry-Leading Immunotherapeutics and Vaccine Research Initiative

March 24, 2016 Aduro Biotech Announces First Patient Dosed in Combination Clinical Trial of CRS-207 and Epacadostat to Treat Ovarian Cancer

March 08, 2016 Aduro Biotech Announces Fourth Quarter and Full Year 2015 Financial Results

March 07, 2016 Aduro Biotech to Present at ROTH Conference

February 03, 2016 Aduro Biotech to Present at Leerink Partners Global Healthcare Conference

February 01, 2016 Aduro Biotech Receives $22.4 Million in Clinical Development Milestone Payments From Janssen

January 25, 2016 Aduro Biotech Appoints Aimee Luck Murphy as Vice President of Clinical Development and Operations

January 07, 2016 Aduro Biotech to Present at JP Morgan Healthcare Conference

January 05, 2016 Aduro Biotech Expands Patent Portfolio With Key Newly Issued Composition and Methods Patents